Latest News on USNA

Financial News Based On Company


Advertisement
Advertisement

USNA: Amendment: SEC Form 10-Q/A filed by USANA Health Sciences Inc.

https://quantisnow.com/insight/amendment-sec-form-10-qa-filed-by-usana-health-sciences-inc-6800460
USANA Health Sciences Inc. (USNA) filed Amendment No. 1 on Form 10-Q/A for the quarter ended October 3, 2026, restating a $29.1 million goodwill impairment related to its Hiya reporting unit from Q2 2026. The amendment also clarifies EBITDA covenant levels, which are set to rise to $100 million after July 4, 2026. Despite the impairment, the company maintains confidence in Hiya's future.

A CFO signature on an exhibit certification is the only change to USANA (USNA)’s Q3 report.

https://www.stocktitan.net/sec-filings/USNA/10-q-a-usana-health-sciences-inc-amended-quarterly-earnings-report-c6388887de65.html
USANA Health Sciences (USNA) amended its Q3 2026 report to include the Chief Financial Officer's conformed signature on an exhibit certification, with no other changes to the original filing. For the quarter ended October 3, 2026, the company reported net sales of $205.885 million, a 3.6% decrease year-over-year, and a net loss attributable to USANA of $5.556 million, an improvement from $6.522 million in the prior year. The nine-month period saw a net loss of $19.423 million, including a non-cash goodwill impairment of $29.137 million for its Hiya segment.

USNA: Amendment: SEC Form 10-Q/A filed by USANA Health Sciences Inc.

https://www.quantisnow.com/insight/amendment-sec-form-10-qa-filed-by-usana-health-sciences-inc-6800460
USANA Health Sciences Inc. (USNA) filed an Amendment No. 1 on Form 10-Q/A for the quarter ended October 3, 2026, restating a $29.1 million non-cash goodwill impairment charge related to its Hiya reporting unit from Q2 2026. The amendment also clarifies EBITDA covenant levels, which are set to rise to $100 million after July 4, 2026. Despite the impairment, the company maintains confidence in Hiya's future performance.

An adviser and two managing members report the same 988,543 USANA (USNA) shares.

https://www.stocktitan.net/sec-filings/USNA/schedule-13g-usana-health-sciences-inc-passive-investment-disclosure--d3bd1c3c2af6.html
Nantahala Capital Management, LLC, an investment adviser, along with its managing members Wilmot B. Harkey and Daniel Mack, have reported beneficial ownership of 988,543 shares of USANA Health Sciences Inc. (USNA). This stake represents 5.35% of the company's class, as detailed in a Schedule 13G SEC filing dated September 30, 2026. Each reporting person holds shared voting and dispositive power over these shares, which are managed through funds and separately managed accounts under Nantahala's control.

Core Nutritional customers fall 8.2% as USANA (USNA) narrows its Q3 loss.

https://www.stocktitan.net/sec-filings/USNA/10-q-usana-health-sciences-inc-quarterly-earnings-report-ac808075b613.html
USANA Health Sciences reported a 3.6% decrease in third-quarter 2026 net sales to $205.9 million, but narrowed its net loss to $5.6 million from $6.5 million a year prior. The Core Nutritional segment saw an 8.2% drop in active customers, while Hiya's sales rose 2.3% and Rise's declined 44.8%. The company recorded a non-cash goodwill impairment charge of $29.1 million for Hiya due to underperformance and revised forecasts.
Advertisement

USANA Health Sciences Reports Q3 2026 Form 10-Q Highlighting Omni-Channel Expansion and Core Business Decline

https://kalkinemedia.com/us/news/announcements/usana-health-sciences-reports-q3-2026-form-10-q-highlighting-omni-channel-expansion-and-core-business-decline
USANA Health Sciences, Inc. (NYSE:USNA) filed its Q3 2026 Form 10-Q, reporting 18,488,751 shares outstanding as of November 6, 2026. The filing highlights a multi-year decline in its core direct sales business while emphasizing its strategic transition to an omni-channel health and wellness model through acquired direct-to-consumer subsidiaries Hiya Health Products, LLC and Rise Wellness, Inc. The report also details operational risks, including those associated with its China-based subsidiary, BabyCare Holdings, Ltd.

USANA Health Sciences (USNA): Q3 2026 10-Q reports net loss and $29.1M goodwill impairment

https://www.quantisnow.com/insight/sec-form-10-q-filed-by-usana-health-sciences-inc-6787344
USANA Health Sciences (USNA) reported a net loss for the three and nine months ended October 3, 2026, and a $29.1 million non-cash goodwill impairment charge on its Hiya reporting unit during Q2 2026 due to weaker performance and lower forecasts. Despite the write-down, the company remains confident in Hiya's strategic importance and has a remaining buyback authorization of $33,965 thousand. However, it must adhere to minimum EBITDA levels and a maximum funded debt to EBITDA ratio as per its credit agreement.

USANA 3Q 2026: Revenue $205.89M, EPS ($0.3) — 10-Q Summary

https://www.tradingview.com/news/tradingview:181498c5b24f8:0-usana-3q-2026-revenue-205-89m-eps-0-3-10-q-summary/
USANA's revenue decreased by 3.6% in 3Q 2026, totaling $205.89 million, while its net loss narrowed by $0.9 million year over year. The company reported a diluted EPS of ($0.3). Sales declines in Core Nutritional and Rise segments were partially offset by growth in Hiya, with overall operating expenses decreasing despite a higher effective tax rate.

USANA Health Sciences, Inc. (USNA) Seasonal Returns Chart - Yahoo Finance

https://ca.finance.yahoo.com/quote/USNA/seasonality/
This article provides a historical seasonality chart for USANA Health Sciences, Inc. (USNA), displaying the average monthly price return from 2016 to 2026. It shows the current stock price and highlights its performance at market close and in after-hours trading. The page also offers various financial data and research options for the company.

USANA Health Sciences Q3 Earnings Call Highlights

https://www.tradingview.com/news/marketbeat:a0484e9df094b:0-usana-health-sciences-q3-earnings-call-highlights/
USANA Health Sciences anticipates 2026 net sales near $900 million and adjusted EBITDA of approximately $77 million, a reduction from previous forecasts, primarily due to weaker performance at Rise Wellness and increased marketing for Hiya, despite stronger core nutrition profitability. The company is transitioning towards an omnichannel health and wellness model, focusing on customer acquisition in core nutrition while expanding Hiya and Rise Wellness through retail and Amazon. While Hiya shows subscriber growth and improving sales in Southeast Asia Pacific, core nutrition faces customer declines, particularly in Greater China, and Rise Wellness orders fell short of expectations.
Advertisement

USANA Health Sciences, Inc. (USNA) stock price, news, quote and history

https://au.finance.yahoo.com/quote/USNA/
This article provides a detailed overview of USANA Health Sciences, Inc. (USNA) stock, including its current price, recent performance, and key financial metrics. As of November 6, 2026, USNA's stock closed at $13.63, down 1.66%, with an overnight gain to $14.04. The company develops and sells nutritional, personal care, and skincare products globally, and its financial performance shows a recent quarterly revenue of $205.88 million and a profit margin of -2.70%.

USANA Health Sciences (NYSE:USNA) Cut to Strong Sell at Zacks Research

https://www.marketbeat.com/instant-alerts/analyst-usana-health-sciences-nyse-usna-cut-to-strong-sell-at-zacks-research-2026-11-06/
Zacks Research has downgraded USANA Health Sciences (NYSE:USNA) to a "strong sell" rating, citing the company's recent miss on earnings and revenue expectations. The company reported a loss of $0.11 per share against an expected $0.11 earnings, with revenue also falling short of estimates. Following these results, USANA also lowered its full-year 2026 outlook, projecting weaker near-term performance.

USANA Health Sciences, Inc. Just Missed Earnings; Here's What Analysts Are Forecasting Now

https://simplywall.st/stocks/us/household/nyse-usna/usana-health-sciences/news/usana-health-sciences-inc-just-missed-earnings-heres-what-an
USANA Health Sciences, Inc. (NYSE:USNA) recently reported quarterly results, missing revenue expectations at US$206m and posting a statutory loss of US$0.30 per share. Despite this, the sole analyst covering the company has maintained their 2027 revenue forecast of US$945.0m and earnings per share of US$1.29, along with a reconfirmed price target of US$25.00, suggesting no significant change in their long-term outlook for the business. The company is expected to grow faster in the future than in the past, though still slower than the broader industry.

USANA BiOmega Earns ConsumerLab Seal of Approval for Quality and Purity

https://www.hjnews.com/news/state/usana-biomega-earns-consumerlab-seal-of-approval-for-quality-and-purity/article_ecab82a1-84a9-5d43-bae9-e266cea34d1a.html
USANA Health Sciences announced that its BiOmega omega-3 supplement has once again received the ConsumerLab Seal of Approval, validating the company's commitment to product quality, purity, and label accuracy. The product passed ConsumerLab's rigorous independent testing, which evaluated EPA and DHA concentration and freshness. This marks a continued history of independent recognition for BiOmega and highlights USANA's broader commitment to third-party verification and stringent internal quality control.

USANA Updates 2026 Outlook With Sales Near $900 Million, Adjusted EBITDA About $77M

https://www.tokenpost.com/news/business/49345
USANA Health Sciences, Inc. has updated its fiscal 2026 outlook, projecting consolidated net sales close to $900 million and adjusted EBITDA around $77 million. This revised outlook accounts for softer expectations for Rise Wellness and increased marketing investment in Hiya, although these pressures are partially offset by stronger profitability in Core Nutritional. The company noted an 18% sequential growth in Hiya's active monthly subscribers but also an 8% year-over-year decline in its overall active customer count, primarily in Greater China, making customer growth a top priority.
Advertisement

USANA Reports Q3 2026 Financial Results

https://www.directsellingnews.com/2026/11/04/usana-reports-q3-2026-financial-results/
USANA Health Sciences, Inc. announced mixed financial results for Q3 2026, with total net sales down to $206 million from $214 million year-over-year, and a net loss of $5.6 million. The company reported encouraging early returns on Hiya customer acquisition investments, adding 29,500 net active monthly subscribers and more than doubling Hiya product sales through Target and Amazon. USANA highlighted rebuilding its active customer base as its top priority, with CEO Kevin Guest noting progress in some areas despite overall results falling short of expectations.

Usana Health Sciences Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/62873820/usana-health-sciences-q3-2026-earnings-call-transcript
Usana Health Sciences reported mixed third-quarter results for 2026, showing improved operating profitability and growth in Southeast Asia Pacific, but facing challenges in Greater China and other regions. The company is transitioning from a single-channel direct selling model to a diversified omnichannel health and wellness approach focused on consumer acquisition and loyalty. Despite some setbacks, particularly with Rise Wellness, the company maintains a strong cash position and no debt, allowing for continued investment in its strategic initiatives.

Why USANA (USNA) shares are sliding today

https://www.tradingview.com/news/stockstory:6aee7bf1e094b:0-why-usana-usna-shares-are-sliding-today/
USANA Health Sciences (USNA) shares fell 4.4% after the company reported a net loss of $5.6 million and a 4% decline in net sales for the third quarter of 2026. The company also updated its full-year 2026 financial guidance downwards, leading to investor concern over its near-term profitability. This follows a significant 29.5% drop three months ago when Q2 2026 results missed Wall Street expectations.

Sales fall 4% as USANA (USNA) raises its full-year loss forecast.

https://www.stocktitan.net/sec-filings/USNA/8-k-usana-health-sciences-inc-reports-material-event-038ce5f0d675.html
USANA Health Sciences (USNA) reported a 4% year-over-year decline in third-quarter 2026 net sales to $206 million, resulting in a net loss of $5.6 million. The company has updated its fiscal year 2026 guidance, now forecasting consolidated net sales approaching $900 million and an increased net loss of $16 million. Despite overall sales declines, USANA saw sequential growth in Hiya active monthly subscribers and an expanded operating margin in its Core Nutritional business.

USANA Health: Q3 Earnings Snapshot

https://uk.finance.yahoo.com/news/usana-health-q3-earnings-snapshot-211858053.html
USANA Health Sciences Inc. (USNA) reported a third-quarter loss of $5.6 million, or 30 cents per share, adjusted to 11 cents per share. The nutritional supplement maker achieved revenue of $205.9 million in the period. For the full year, USANA Health anticipates earnings of 55 cents per share and revenue of $900 million.
Advertisement

USANA Health Sciences earnings missed by $0.54, revenue fell short of estimates

https://uk.investing.com/news/earnings/usana-health-sciences-earnings-missed-by-054-revenue-fell-short-of-estimates-4953849
USANA Health Sciences (NYSE: USNA) reported third-quarter EPS of $-0.11, missing analyst estimates by $0.54, with revenue also falling short at $206M against a $219.02M consensus. The company's stock has declined significantly over the past year, and it has issued lower-than-expected guidance for FY 2026 EPS and revenue. InvestingPro rates USANA Health Sciences' financial health as "fair performance."

USANA Health Sciences Reports Third Quarter 2026 Results

https://uk.finance.yahoo.com/news/usana-health-sciences-reports-third-210500412.html
USANA Health Sciences announced mixed financial results for Q3 2026, with net sales of $206 million, down from $214 million year-over-year, and a net loss of $(5.6) million. Despite a decline in Core Nutritional active customers, the Hiya segment saw an 18% sequential increase in active monthly subscribers and year-over-year net sales growth. The company updated its fiscal 2026 guidance to net sales approaching $900 million and Adjusted EBITDA of $77 million, reflecting strategic investments in Hiya for future growth.

USANA (NYSE:USNA) misses Q3 2026 revenue estimates, stock drops 14.9%

https://markets.financialcontent.com/stocks/article/stockstory-2026-11-3-usana-nyseusna-misses-q3-2026-revenue-estimates-stock-drops-149
USANA Health Sciences (NYSE: USNA) missed Wall Street's Q3 2026 revenue expectations, with revenue falling 3.6% year-on-year to $205.9 million and full-year guidance also lowered. The company also reported a non-GAAP loss of $0.11 per share, significantly below analyst estimates. Following the announcement, USANA's shares plunged 14.9% to $12.65.

USANA BiOmega Earns ConsumerLab Seal of Approval for Quality and Purity

https://www.morningstar.com/news/pr-newswire/20261103la82540/usana-biomega-earns-consumerlab-seal-of-approval-for-quality-and-purity
USANA Health Sciences' BiOmega omega-3 supplement has again received the ConsumerLab Seal of Approval, validating its quality, purity, and label accuracy through independent testing. This recognition highlights USANA's commitment to rigorous testing and manufacturing standards, reinforcing consumer confidence in its products. BiOmega met ConsumerLab's stringent quality standards, continuing a history of independent recognition for the product.

USANA BiOmega Earns ConsumerLab Seal of Approval for Quality and Purity

https://www.prnewswire.com/news-releases/usana-biomega-earns-consumerlab-seal-of-approval-for-quality-and-purity-302921913.html
USANA Health Sciences' BiOmega omega-3 supplement has received the ConsumerLab Seal of Approval for its quality, purity, and label accuracy. This independent third-party validation reinforces USANA's commitment to rigorous product testing and adherence to high manufacturing standards. The company emphasizes that this recognition provides consumers with increased confidence in the quality of its nutritional products.
Advertisement

USANA launches 3-in-1 protein, creatine, electrolyte drink mix

https://scanx.trade/stock-market-news/companies/usana-launches-3-1-protein-creatine-electrolyte-drink-mix/48513504
USANA Health Sciences has introduced Clear Protein + Creatine Mix, a new 3-in-1 beverage combining 10g of protein, 5g of creatine, and over 600mg of electrolytes in a 50-calorie serving. This product aims to simplify daily nutrition for active adults by replacing multiple supplements with a single, refreshing drink, available in Twisted Citrus and Green Apple flavors. The formula is research-backed, contains no added sugar or artificial ingredients, and is endorsed by Olympic athlete Chris Mazdzer.

As Thanksgiving Nears, USANA CEO Kevin Guest Urges All to Rethink What Success Really Means

https://www.prnewswire.com/news-releases/as-thanksgiving-nears-usana-ceo-kevin-guest-urges-all-to-rethink-what-success-really-means-302921901.html
USANA Health Sciences Chairman and CEO Kevin Guest is encouraging people to redefine success beyond material achievements as Thanksgiving approaches. Drawing from his book "All the Right Reasons," Guest emphasizes that true success lies in experiences, relationships, and lessons learned. He suggests three ways to practice this "Journey Principle": thanking those who've shaped one's life, making time for meaningful connections, and recognizing the value of unexpected lessons.

USANA (USNA) Q3 earnings report preview: what to look for

https://www.tradingview.com/news/stockstory:d196138d4094b:0-usana-usna-q3-earnings-report-preview-what-to-look-for/
USANA Health Sciences (USNA) is preparing to report its Q3 earnings, with analysts expecting revenue growth of 1.8% year-on-year. The company previously missed revenue expectations but beat EBITDA estimates last quarter. Sentiment in the consumer staples segment has been positive, though USANA's stock is down 3.6% over the last month, trading significantly below its average analyst price target.

USANA (USNA) Q3 earnings report preview: what to look for

https://markets.financialcontent.com/stocks/article/stockstory-2026-11-2-usana-usna-q3-earnings-report-preview-what-to-look-for
USANA Health Sciences (NYSE: USNA) is set to report its Q3 earnings, with analysts expecting a 1.8% year-on-year revenue growth. The company missed revenue expectations last quarter but beat EBITDA estimates. Investors will be watching closely as USANA has an average analyst price target significantly higher than its current share price, despite recent underperformance in share price compared to its consumer staples peers.

USANA Health Sciences (USNA) Set to Release Quarterly Earnings on Tuesday

https://www.marketbeat.com/instant-alerts/upcoming-usana-health-sciences-usna-set-to-release-quarterly-earnings-on-tuesday-2026-10-27/
USANA Health Sciences (USNA) is scheduled to release its Q3 2026 earnings after market close on Tuesday, November 3rd, with analysts forecasting earnings of $0.11 per share on $217.42 million in revenue. This follows a disappointing previous quarter where the company missed expectations significantly, reporting a $0.07 per-share loss. Analyst sentiment remains cautious, with an average "Reduce" rating and shares having dropped from a 12-month high of $23.59 to approximately $14.04.
Advertisement

Form 4 USANA Health Sciences Inc: Frederic J. Winssinger (Director) For: 22 October

https://ng.investing.com/news/stock-market-news/form-4-usana-health-sciences-inc-frederic-j-winssinger-director-for-22-october-93CH-2755591
This article reports on a Form 4 filing for USANA Health Sciences Inc., specifically detailing transactions made by director Frederic J. Winssinger on October 22. Form 4 filings are regulatory documents that disclose changes in the ownership of company stock by insiders. The article indicates this is a standard disclosure of insider trading activity.

After acquiring 1,632 shares, USANA (USNA) director Fuller holds 3,264 common shares.

https://www.stocktitan.net/sec-filings/USNA/form-4-usana-health-sciences-inc-insider-trading-activity-0cda9ba37b21.html
USANA Health Sciences Inc. director Gilbert A. Fuller converted 1,632 restricted stock units into common stock on October 22, 2026. This transaction increased his direct holdings to 3,264 common shares, with an additional 3,263 restricted stock units remaining. The restricted stock units are scheduled to vest 25% on four dates from July 23, 2026, through April 22, 2027.

Form 4 USANA Health Sciences Inc: Frederic J. Winssinger (Director) For: 22 October By Investing.com

https://za.investing.com/news/stock-market-news/form-4-usana-health-sciences-inc-frederic-j-winssinger-director-for-22-october-93CH-4523695
This article reports a Form 4 filing for USANA Health Sciences Inc., specifically concerning Director Frederic J. Winssinger, with the reported activity date being October 22nd. Form 4 filings are used to disclose changes in beneficial ownership of a company's securities by insiders. The article indicates a 3.86% dip for USNA (USANA Health Sciences Inc.) shares.

USANA Health Sciences, Inc. Estimates – NYSE:USNA

https://www.tradingview.com/symbols/NYSE-USNA/financials-estimates/
This article provides an overview of USANA Health Sciences, Inc. (NYSE: USNA) financial data, including statements, statistics, estimates, dividends, and earnings. It allows users to explore reported financial data and analyst estimates across various financial statements and valuation metrics. The platform enables comparison of actual results with average, high, and low estimates, and visualization of trends over time.

Form 4 USANA Health Sciences Inc: J. Scott Nixon (Director) For: 22 October

https://au.investing.com/news/stock-market-news/form-4-usana-health-sciences-inc-j-scott-nixon-director-for-22-october-93CH-4712457
This article reports on a Form 4 filing for USANA Health Sciences Inc., specifically detailing a transaction involving director J. Scott Nixon on October 22nd. The filing indicates insider activity for the company, which is often monitored by investors for insights into a company's health and future prospects.
Advertisement

Zacks upgrades USANA Health Sciences stock from strong sell to hold

https://www.ad-hoc-news.de/boerse/news/nebenwerte/zacks-upgrades-usana-health-sciences-stock-from-strong-sell-to-hold/70373753
Zacks Research has upgraded USANA Health Sciences (USNA) stock from "strong sell" to "hold" on October 7, 2026, despite the company reporting second-quarter 2026 net sales below consensus estimates. USANA's second-quarter revenue was USD 223.27 million against a USD 235.00 million consensus, with diluted earnings per share at minus USD 1.16. The company recently secured a new revolving credit facility and is scheduled to release third-quarter results on November 3, 2026.

China unites modern nutritional science with traditional medicine

https://nuffoodsspectrum.asia/news/28/1770/china-unites-modern-nutritional-science-with-traditional-medicine.html
USANA Health Sciences, Inc., and its Chinese subsidiary, BabyCare, Ltd., have formed a research collaboration with Beijing University of Chinese Medicine (BUCM). The partnership aims to integrate modern nutritional science with Traditional Chinese Medicine (TCM) to develop new health products and nutritional regimens. This collaboration will also support academic exchange and promote TCM globally.

USANA schedules third-quarter results for USANA Health Sciences stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/usana-schedules-third-quarter-results-for-usana-health-sciences-stock/70353667
USANA Health Sciences (USNA) has scheduled its third-quarter 2026 results release for November 3, 2026, after market close, with a conference call set for November 4, 2026. This announcement follows a second quarter where the company reported sales of USD 223.27 million and a diluted EPS of minus USD 1.16, falling short of analyst consensus. The upcoming results will be crucial in assessing whether the previous quarter's loss was temporary or indicative of a larger earnings trend.

USANA sets November 3 results date for USANA Health Sciences stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/usana-sets-november-3-results-date-for-usana-health-sciences-stock/70329153
USANA Health Sciences (USNA) will release its third-quarter 2026 results after market close on November 3, 2026, following a net loss in Q2 primarily due to a significant impairment charge. The stock was trading at EUR 13.55 on October 15, 2026. Investors will be looking for an update on sales, earnings, and the impact of the impairment charge in the upcoming report and subsequent conference call.

USANA Schedules Third Quarter 2026 Earnings Release and Conference Call

https://www.businesswire.com/news/home/20261012352954/en/USANA-Schedules-Third-Quarter-2026-Earnings-Release-and-Conference-Call
USANA Health Sciences, Inc. (NYSE:USNA) announced that its third-quarter 2026 financial results will be released after market close on Tuesday, November 3, 2026. The company will also host a conference call for analysts and investors on Wednesday, November 4, 2026, at 11:00 a.m. Eastern Time, accessible via its Investor Relations website. USANA is a health and wellness company specializing in nutritional supplements, functional foods, and personal care products, and holds ownership stakes in Hiya Health Products and Rise Wellness.
Advertisement

How Usana Health Sciences Inc. (USNA) Affects Rotational Strategy Timing

https://news.stocktradersdaily.com/news_release/21/How_Usana_Health_Sciences_Inc._USNA_Affects_Rotational_Strategy_Timing_101026051602_1791623762.html
The article analyzes Usana Health Sciences Inc. (USNA) using AI models to determine its effect on rotational strategy timing. It identifies a stable neutral reading in shorter horizons, suggesting an easing of a long-term weak bias, and details three distinct trading strategies (Position, Momentum Breakout, Risk Hedging) tailored for different risk profiles. The analysis highlights an exceptional risk-reward setup targeting a 20.8% gain versus a 0.3% risk.

USANA Health Sciences and University of Utah Athletics Announce New Partnership

https://www.prnewswire.com/news-releases/usana-health-sciences-and-university-of-utah-athletics-announce-new-partnership-302899470.html
USANA Health Sciences and University of Utah Athletics have forged a new partnership, uniting two Utah-based organizations with a shared commitment to health, performance, and excellence. This collaboration will provide nutritional products and NIL opportunities to over 500 University of Utah student-athletes across 19 sports, significantly expanding USANA's roster of sponsored elite athletes. The partnership also includes community-focused initiatives through the USANA Foundation, reinforcing the companies' dedication to local impact.

USANA Health Sciences and University of Utah Athletics Announce New Partnership

https://finance.yahoo.com/healthcare/articles/usana-health-sciences-university-utah-110600246.html
USANA Health Sciences and University of Utah Athletics have formed a new partnership to support over 500 student-athletes across 19 sports. This collaboration will provide student-athletes with nutritional products, NIL opportunities, and community involvement through the USANA Foundation. The partnership brings USANA's commitment to athletes closer to its Utah roots, with founder Dr. Myron Wentz being an alumnus of the University of Utah.

USANA Partners with University of Utah to Support Student Athletes

https://www.directsellingnews.com/2026/10/07/usana-partners-with-university-of-utah-to-support-student-athletes/
USANA Health Sciences has announced a partnership with University of Utah Athletics to support over 500 student-athletes. This collaboration will provide nutritional products, NIL opportunities, and community initiatives, aiming to improve athlete health and performance while building their personal brands. The partnership holds special significance as USANA's founder, Dr. Myron Wentz, is an alumnus of the University of Utah.

USANA Health Sciences (NYSE:USNA) Upgraded at Zacks Research

https://www.marketbeat.com/instant-alerts/analyst-usana-health-sciences-nyse-usna-upgraded-at-zacks-research-2026-10-07/
Zacks Research upgraded USANA Health Sciences (NYSE:USNA) from a "strong sell" to a "hold" rating, though the broader analyst consensus remains "Reduce." The company recently reported a quarterly loss of $0.07 per share, missing analysts' consensus estimates, with revenue also falling short. USNA's stock opened at $14.91, near its 52-week low, and institutional investors own approximately 54.25% of the company.
Advertisement

USANA partners with University of Utah to support 500+ student-athletes with nutrition and community programs

https://pluang.com/en/news-feed/usana-health-sciences-dan-university-of-utah-athletics-umumkan-kemitraan-baru
USANA Health Sciences has announced a partnership with University of Utah Athletics to provide over 500 student-athletes with high-quality nutritional products, NIL opportunities, and community involvement through the USANA Foundation. This collaboration aims to enhance athlete health, performance, and personal brand development, while also supporting the university's Performance Nutrition program. The initiative reinforces USANA's commitment to athlete support, particularly in its home state.

Nutrition and brand-building support for 500+ Utah athletes will come through a USANA partnership.

https://www.stocktitan.net/news/USNA/usana-health-sciences-and-university-of-utah-athletics-announce-new-hh823gtmd1et.html
USANA Health Sciences and University of Utah Athletics have announced a new partnership to support over 500 student-athletes across 19 sports. This collaboration will provide nutritional products, name, image, and likeness (NIL) opportunities, and community-focused initiatives. The partnership also aims to connect student-athletes with the USANA Foundation for local community involvement, further expanding USANA's commitment to elite athletes.

USANA expands Utah partnership: what it means for USANA Health Sciences stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/usana-expands-utah-partnership-what-it-means-for-usana-health-sciences-stock/70250906
USANA Health Sciences has expanded its partnership with Utah Athletics to support over 500 student-athletes across 19 sports, providing nutritional products and marketing opportunities. This local marketing boost comes as the company faces a challenging second quarter with declining sales and a significant loss per share, highlighting the need for sales stabilization. USANA also amended its credit agreement, setting a higher profitability hurdle, and its third-quarter results will be closely watched for financial stability.

The annual general asset-sale limit rises to $2.5M in book value under USANA (USNA)'s credit amendment.

https://www.stocktitan.net/sec-filings/USNA/8-k-usana-health-sciences-inc-reports-material-event-daffa440da0d.html
USANA Health Sciences, Inc. (USNA) amended its $75 million revolving credit facility, increasing the annual general asset-sale limit from $500,000 to $2.5 million in aggregate book value. The amendment also permits USANA Australia Pty, Ltd to sell its real property in Sydney and use the proceeds, while introducing a new Consolidated EBITDA covenant starting October 3, 2026. This filing, classified as a material event, details changes to financial obligations and certain permitted transactions.

USANA Health Sciences stock reports a Q2 loss before October results

https://www.ad-hoc-news.de/boerse/news/corporate-news/usana-health-sciences-stock-reports-a-q2-loss-before-october-results/70240826
USANA Health Sciences reported a Q2 2026 loss with diluted EPS of negative USD 1.16, compared to a positive USD 0.52 a year prior, on sales of USD 223.3 million, a 5.3% year-over-year decline. The company's operating margin was negative 9% for the quarter, though operating cash flow remained positive at USD 23.3 million. Investors are looking to the upcoming Q3 2026 earnings report on October 28, 2026, to see if sales stabilize amidst pressures in its nutrition and direct-to-consumer businesses.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement